United Kingdom - English - myHealthbox

actavis group ptc ehf - butamirate citrate - syrup - 7.5mg/5ml - other cough suppressants - symptomatic treatment of non-productive cough.

Bangladesh - English - DGDA (Directorate General of Drug Administration)

eskayef pharmaceuticals ltd., tongi,gazipur - butamirate citrate - syrup - 150 mg/100 ml

Bangladesh - English - DGDA (Directorate General of Drug Administration)

eskayef pharmaceuticals ltd., tongi,gazipur - butamirate citrate - oral drops - 500 mg/100 ml

United States - English - NLM (National Library of Medicine)

rebel distributors corp - pramipexole dihydrochloride (unii: 3d867np06j) (pramipexole - unii:83619peu5t) - pramipexole dihydrochloride 0.500 mg - mirapex® (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinson's disease. the effectiveness of mirapex tablets was demonstrated in randomized, controlled trials in patients with early parkinson's disease who were not receiving concomitant levodopa therapy as well as in patients with advanced disease on concomitant levodopa (see clinical studies ). mirapex tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). key diagnostic criteria for rls are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. difficulty falling asleep may frequently be associated with symptoms of rls. mir

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - pramipexole dihydrochloride (unii: 3d867np06j) (pramipexole - unii:83619peu5t) - pramipexole dihydrochloride 0.500 mg - mirapex® (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinson's disease. the effectiveness of mirapex tablets was demonstrated in randomized, controlled trials in patients with early parkinson's disease who were not receiving concomitant levodopa therapy as well as in patients with advanced disease on concomitant levodopa (see clinical studies ). mirapex tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). key diagnostic criteria for rls are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. difficulty falling asleep may frequently be associated with symptoms of rls. mir

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: n/a; distributor: mdb pharma trading - butamirate citrate - sustained-release tablet - 50 mg

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: nelpa lifesciences, inc.; distributor: nelpa lifesciences, inc. - butamirate citrate - sustained-release tablet - 50 mg

United States - English - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - pramipexole dihydrochloride (unii: 3d867np06j) (pramipexole - unii:83619peu5t) - pramipexole dihydrochloride 0.125 mg - mirapex tablets are indicated for the treatment of parkinson's disease. mirapex tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). none. risk summary there are no adequate data on the developmental risk associated with the use of mirapex in pregnant women. no adverse developmental effects were observed in animal studies in which pramipexole was administered to rabbits during pregnancy. effects on embryofetal development could not be adequately assessed in pregnant rats; however, postnatal growth was inhibited at clinically relevant exposures [see data ]. in the u.s. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal data oral administration of pramipexole (0.1, 0.5, or 1.5 mg/kg/day) to pregnant rats during the period of organogen

Bangladesh - English - DGDA (Directorate General of Drug Administration)

hudson pharmaceuticals ltd. - butamirate citrate - syrup - 150 mg/100 ml

Philippines - English - FDA (Food And Drug Administration)

nelpa lifesciences, inc. - butamirate citrate - syrup (caramel flavor) - 7.5 mg/5 ml